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Abstract 19 
Multidrug-resistance in pathogenic bacteria is an increasing problem in patient care and 20 
public health. Molecular nanomachines (MNM) have the ability to open cell membranes using 21 
nanomechanical action. We hypothesized that MNM could be used as antibacterial agents by 22 
drilling into bacterial cell walls and increasing susceptibility of drug resistant bacteria to recently 23 
ineffective antibiotics. We exposed extensively drug resistant K. pneumoniae to light-activated 24 
MNM and found that MNM increase susceptibility to meropenem. MNM with meropenem can 25 
effectively kill K. pneumoniae that are considered meropenem resistant. We examined the 26 
mechanisms of MNM action using permeability assays and transmission electron microscopy, 27 
finding that MNM disrupt the cell wall of extensively drug resistant K. pneumoniae, exposing the 28 
bacteria to meropenem. These observations suggest that MNM could be used to make conventional 29 
antibiotics more efficacious against multidrug-resistant pathogens. 30 
 31 
Keywords: molecular nanomachines, nanomechanical action, light-activation, antimicrobial, 32 
antimicrobial resistance, multidrug resistance, extensively drug resistance. 33 
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Multidrug-resistant (MDR) pathogens are an increasing problem worldwide. Annually, 35 
700,000 deaths are attributed to MDR and antimicrobial resistant (AMR) strains of common 36 
bacterial infections. This number, if current trends in the use of antibiotics continue, is projected 37 
to increase beyond 10 million annual deaths by 2050,.1 MDR infections create an increasingly 38 
large burden in healthcare and preventative practices.2 In their 2013 antibiotic-resistant threat 39 
report, the Centers for Disease Control and Prevention (CDC) listed 18 MDR and AMR pathogens 40 
that require immediate attention. Carbapenem-resistant Enterobacteriaceae (CRE) were identified 41 
as one of three pathogens at the highest threat level, demanding urgent action.3 Recognizing the 42 
global impact of MDR and AMR pathogens on patient care, the World Health Organization 43 
(WHO) put forth a Global Action Plan (GAP) in 2015 to ensure continued success in effective 44 
treatment and prevention of these infectious diseases.4 In 2017 WHO also identified CRE as one 45 
of three carbapenem-resistant pathogens in their highest priority category (Priority 1: Critical) for 46 
research and development of new antibiotics, again highlighting the urgent need for solutions to 47 
counter pathogens resistant to last resort antibiotics.5 48 
Klebsiella pneumoniae belongs to the family of Enterobacteriaceae and is one of the most 49 
important causes of nosocomial infections worldwide.6 This Gram-negative opportunistic 50 
pathogen colonizes the human intestine and is of high clinical importance, especially among very 51 
sick patients.7 K. pneumoniae causes various healthcare-associated infections, including 52 
pneumonia, bloodstream infections, urinary tract infections, wound or surgical site infections, and 53 
meningitis.8-10 Over the last few decades, MDR K. pneumoniae infections have rapidly increased 54 
in hospital settings, making first-line antibiotics vastly ineffective. The emergence of carbapenem-55 
resistant strains of K. pneumoniae as a major nosocomial infection has raised many concerns as 56 
antibiotic treatment options available against this pathogen are very limited.11-13 With the rapid 57 
4 
emergence of resistance to conventional antibiotics that were once considered wonder drugs, there 58 
is an emergent need for the development of new unconventional antibiotic agents that can 59 
effectively counter MDR pathogens. 60 
Molecular nanomachines (MNM) are synthetic organic nanomolecules that have a rotor 61 
component with light-induced actuation (motorization) that rotates unidirectionally relative to a 62 
stator (Figure 1 a).14-16 These MNM can disrupt synthetic lipid bilayers and cell membranes with 63 
their rapid rotational movement. Recently, ultraviolet light-activated MNM were shown to use 64 
nanomechanical action to drill into cell membranes, creating pores in targeted cancer cells and 65 
causing cell death.17 Light-activated fast motor, MNM 1 (Figure 1 b) was shown to cause cell 66 
necrosis in human prostate adenocarcinoma cells (PC-3) and mouse embryonic fibroblast cells 67 
(NIH 3T3). MNM have various properties depended on their steric structure and attached 68 
functional groups. They can be modified to give them specific properties and functions. Light-69 
activated MNM 1 rotates ~2-3 million revolutions per second and is considered a fast motor. Light-70 
activated MNM 2 is a slow motor rotating only ~1.8 revolutions per hour and is a nanomechanical 71 
control for MNM 1. MNM 3 is similar to MNM 1 but with a triphenylphosphonium (TPP) cation 72 
attached to its stator portion. TPP targets eukaryotic mitochondria causing MNM 3 to accumulate 73 
within mitochondria.18 MNM can also have peptide appendages for specific cell adhesion. 74 
Nanomechanical action of fast motor MNM makes them potential broad-spectrum antibacterials. 75 
We hypothesized that MNM 1 can disrupt bacterial cell walls and act as a potent nanomechanical 76 
antibacterial agent either alone or facilitating the action of conventional antimicrobials. 77 
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 78 
Figure 1. Molecular nanomachine (MNM) structures. (a) A representative MNM illustrating 79 
the rotor portions (red), which rotate upon light-activation relative to the stator portion (blue). R 80 
groups (green) are functional molecules that can be added to provide increased solubility, 81 
fluorophores for tracking or serve as recognition sites for cellular targeting. (b) MNM 1 is a fast 82 
motor with a unidirectional rotor activated by 365 nm light. (c) MNM 2 is the corresponding slow 83 
motor that serves as a control. (d) MNM 3 is a fast motor similar to MNM 1 but with a 84 
triphenylphosphonium (TPP) cation attached to the stator portion. TPP targets eukaryotic 85 
mitochondria causing MNM 3 to accumulate within mitochondria. This served as a control to 86 
demonstrate eukaryotic cell targeting of MNM. 87 
 88 
Among various AMR mechanisms used by MDR K. pneumoniae to resist carbapenems, 89 
the loss of cell wall outer membrane porins and production of K. pneumoniae carbapenemase 90 
(KPC) confer the highest levels of carbapenem resistance.19-22 The cell wall outer membrane (OM) 91 
lacking porins acts as a mechanical barrier that prevents carbapenem to permeate the OM and reach 92 
6 
its target site, penicillin-binding proteins (PBP) in the periplasmic space.23 We explore the use of 93 
light-activated MNM 1 nanomechanical properties to drill pores and disrupt the cell wall in MDR 94 
K. pneumoniae to allow carbapenem to traverse the cell wall OM and cause bacterial cell death. 95 
Here we use an extensively drug resistant (ψkp6) and an antibiotic sensitive (ψkp7) strain 96 
of K. pneumoniae to first show that light-activated MNM 1 using their nanomechanical action, can 97 
display antibacterial properties irrespective of pathogen antibiotic susceptibility profiles. Then we 98 
show that light-activated MNM 1 in combination with meropenem has the ability to make an 99 
extensively drug resistant K. pneumoniae susceptible to meropenem at sub-therapeutic 100 
concentrations. Our results indicate that light-activated MNM 1 uses its nanomechanical action to 101 
assist in bypassing the cell wall OM induced antibacterial resistance posed by K. pneumoniae. 102 
Thus, MNM 1 together with antibiotics like meropenem is shown as a potent antibacterial agent 103 
with the potential to effectively counter the increasing problem of multidrug resistance not only in 104 
K. pneumoniae but in many other MDR pathogens. 105 
 106 
Results and Discussion 107 
Characterization of optimum conditions for MNM light-activation against K. 108 
pneumoniae. The irradiance of the 365 nm LED light source (Sunlite Eagle 8WFP UV365 LED) 109 
used to activate the MNM was constant in the range of 10.5 to 12 mW/cm2 measure over the course 110 
of 60 min at a constant distance (Figure 2 a). It had a narrow wavelength spectrum of 360 to 376 111 
nm, with peak intensity at 368 nm (Figure 2 b). Any effects related to increase in heat due to the 112 
light source was excluded by the used of no MNM and slow MNM controls. Under these 113 
conditions, we assayed the bactericidal effects of the light source on an extensively drug-resistant 114 
K. pneumoniae (ψkp6) and an antibiotic sensitive K. pneumoniae (ψkp7). ψkp6 and ψkp7 115 
7 
antibiotics susceptibilities were characterized against several antibiotics using microdilution 116 
assays (Table 1). With 5 min of light exposure, we observed a viability reduction of 3% in ψkp6 117 
and 6.5% in ψkp7. With 10 min of light exposure, it was 4% in ψkp6 and 18% in ψkp7, and at 60 118 
min 40% in ψkp6 and 55% in ψkp7 (Figure 2 c). The overall bactericidal effects of 356 nm light 119 
on ψkp6 and ψkp7 were not significantly different (p=0.1802). Therefore a 5 min light-activation 120 
time was chosen to minimize the effects of 365 nm light on K. pneumoniae. For viability assays, 121 
120 to 240 µL volumes of bacterial cultures were exposed to light directly placed above it at 122 
distance of 1.3 cm (Figure 2 d). For permeability and toxicity assays the light source was directly 123 
placed above the 96-well plate at a distance of 0.65 cm from the culture or media (Figure 2 e-f). 124 
 125 
Figure 2. Characterization of 365 nm light source used to activate molecular nanomachines 126 
(MNM). (a) The irradiance of the 365 nm light source remained within a constant range of 10.5 to 127 
12 mW/cm2 measured over 1 h. (b) The range of wavelengths emitted by the 365 nm light source 128 
and their relative intensities with peak light intensity at 368 nm wavelength. (c) Bactericidal effect 129 
of the 365 nm light source on K. pneumoniae over 60 min of light exposure. ψkp6 (AR-0666), an 130 
8 
extensively drug-resistant strain of K. pneumoniae. ψkp7 (NIH-1), an antibiotic sensitive strain of 131 
K. pneumoniae. Percent survival was calculated by dividing the CFU/mL at each time point by the 132 
starting CFU/mL. A Mann-Whitney test was used to compare the survival of ψkp6 (AR-0666) and 133 
ψkp7 (NIH-1) strains (p=0.1802) (d) The light source placed directly above bacterial cultures at a 134 
constant distance of 1.3 cm for the duration of light exposure. (e-f) The light source placed directly 135 
above the 96-well plate to only expose four wells as shown by the inserts.  136 
 137 
Table 1. Antibiotic susceptibilities of K. pneumoniae strains ψkp7 (NIH-1) and ψkp6 (AR-138 
0666). 139 
  ψkp7a ψkp6b 












        
Meropenem Carbapenem 0.0625 0.0625 S(-) 16 16 R(+) 
Tetracycline Tetracycline 8 4 S(-) 256 256 R(+) 
Gentamicin Aminoglycoside 1 1 S(-) > 512 > 512 R(+) 
Amikacin Aminoglycoside 1 1 S(-) > 512 > 512 R(+) 
Streptomycin Aminoglycoside 4 4 S(-) 4 4 S(-) 
Hygromycin Aminoglycoside 64 64 S(-) 32 32 S(-) 
Kanamycin Aminoglycoside 2 2 S(-) > 512 > 512 R(+) 
Spectinomycin Aminoglycoside 32 64 S(-) 64 > 512 R(+) 
Rifampin Rifamycins 32 32 R(+) 16 16 R(+) 
Isoniazid Isonicotinate > 128 > 128 R(+) > 128 > 128 R(+) 
9 
Ampicillin Penicillin > 512 > 512 R(+) > 512 > 512 R(+) 
Vancomycin Glycopeptide > 128 > 128 R(+) > 128 > 128 R(+) 
aψkp7 strain (NIH-1), carbapenemase non-producing (KPC negative), antibiotic sensitive strain 140 
obtained from NIH. 141 
bψkp6 strain (AR-0666), carbapenemase producing (KPC positive), extensively drug-resistant 142 
strain obtained from the CDC. 143 
cMinimal inhibitory concentration (MIC), the lowest concentration needed to inhibit bacterial 144 
growth determined by colony forming units (CFU). 145 
dMinimal bactericidal concentration (MBC99), the lowest concentration needed to kill 99% of the 146 
bacteria determined by CFU. 147 
eAntibiotic susceptibility testing (AST): S(-) – sensitive, R(+) – resistant. 148 
 149 
Light-activated MNM 1 cause reduced bacterial viability through its fast rotational 150 
movement in K. pneumoniae. To characterize the antibacterial properties of MNM 1, we exposed 151 
the extensively drug-resistant (ψkp6) and the antibiotic sensitive (ψkp7) K. pneumoniae strains to 152 
10 µM of MNM 1 (fast motor), MNM 2 (slow motor) control and to the MNM solvent of 0.1% 153 
dimethyl sulfoxide (DMSO) control (no MNM), with 5 min of 365 nm light-activation (Figure 3 154 
a). DMSO solvent was used so that the MNM remain soluble in media and DMSO at 155 
concentrations of 0.1% has no effects on cell viability.17  The only significant reduction in CFU 156 
counts was observed in light-activated MNM 1 for both ψkp6 and ψkp7 (p= 0.0219 and 0.0078 157 
respectively) (Figure 3 b-c). The percent viability reduction of ψkp6 exposed to light-activated 158 
MNM 1 was 21.3%, significantly higher than that of the no MNM (DMSO) control (5.4%) and 159 
MNM 2 control (4.6%) (Figure 3 b). Similarly, the percent viability reduction of ψkp7 exposed to 160 
10 
light-activated MNM 1 was 27.2%, significantly higher than that of the no MNM control (12.9%) 161 
and MNM 2 control (12.7%) (Figure 3 c). No toxicity or bactericidal effects were observed when 162 
10 µM of non-light-activated MNM 1 was exposed to either ψkp6 or ψkp7. These results show 163 
that high-speed rotation of light-activated MNM 1 nanomechanical damage to K. pneumoniae 164 
irrespective of their antibiotic susceptibility, causing a significant relative reduction in viability 165 
(14-17%). In contrast, neither the light-activated MNM 2 nor the non-activated MNM 1 caused a 166 
significant reduction in viability. Our results showed no significant difference in the viability 167 
reduction observed in K. pneumoniae irrespective of their antibiotic sensitivity profiles. This 168 
suggests that antimicrobial resistance (AMR) mechanisms of this extensively-drug resistant strain 169 
have little or no effect on the nanomechanical action of light-activated MNM 1. 170 
 171 
Figure 3. Viability reduction of K. pneumoniae with light-activated molecular nanomachines 172 
(MNM). (a) Experimental setup for bacterial viability reduction assays. A log growth phase culture 173 
11 
of K. pneumoniae incubated with no MNM (dimethyl sulfoxide (DMSO)), MNM 2 or MNM 1 for 174 
30 min, activated with 365 nm light for 5 min and plated for CFU/mL counts. (b) An extensively 175 
drug-resistant strain of K. pneumoniae (ψkp6, AR-0666) exposed to no MNM (DMSO), 10 µM of 176 
MNM 2 or 10 µM of MNM 1. Comparison of CFU/mL of K. pneumoniae after MNM exposure, 177 
without- and with-light activation. (c) An antibiotic sensitive strain of K. pneumoniae (ψkp7, NIH-178 
1) exposed to no MNM (DMSO), 10 µM of MNM 2 or 10 µM of MNM 1. Comparison of CFU/mL 179 
of K. pneumoniae after MNM exposure, without- and with-light activation. Results presented are 180 
means and standard error from four replicates for each group. p-values are from unpaired two-181 
tailed Student t-test. 182 
 183 
Light-activated MNM 1 causes cell wall inner and outer membrane disruptions in K. 184 
pneumoniae. To confirm the viability reduction observed in K. pneumoniae is a result of cell wall 185 
disruptions caused by the fast drilling action of light-activated MNM 1, we carried out three assays 186 
to characterize the cell wall inner membrane permeability, outer membrane permeability, and cell 187 
membrane integrity. Cell wall inner membrane permeability of K. pneumoniae exposed to no 188 
MNM (DMSO control), 10 µM of MNM 2 or 10 µM of MNM 1 was determined using o-189 
nitrophenyl-β-D-galactoside (ONPG), which is a substrate to cytoplasmic β-galactosidase that 190 
would leak through the cell wall inner membrane when disrupted. In both the extensively drug-191 
resistant (ψkp6) and the antibiotic sensitive (ψkp7) K. pneumoniae, light-activated MNM 1 showed 192 
a significant increase in the β-galactosidase activity represented by an increase in absorbance at 193 
410 nm wavelength (Figure 4 a-b). This was in contrast to both the light-activated MNM 2 and the 194 
non-activated MNM 1 that did not cause a significant increase in absorbance at 410 nm. To further 195 
characterize these differences, we calculated the differences in β-galactosidase activity at 30 min 196 
12 
post-exposure in Miller units.24 In both ψkp6 and ψkp7, light-activated MNM 1 showed a 197 
significant increase in inner membrane permeability compared to non-activated MNM 1, MNM 2 198 
and no MNM (DMSO) control (Figure 4 c-d). These results indicate that upon light-activation, 199 
MNM 1 causes nanomechanical damage to K. pneumoniae cell wall inner membrane allowing the 200 
leakage of cytoplasmic β-galactosidase enzyme. 201 
 202 
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Figure 4. Cell wall inner membrane permeability with and without light-activation of 203 
molecular nanomachines (MNM). Cell wall inner membrane permeability of K. pneumoniae 204 
exposed to no MNM (DMSO), 10 µM of MNM 2 or 10 µM of MNM 1 determined by cytoplasmic 205 
β-galactosidase activity using o-nitrophenyl-β-D-galactoside (ONPG) as the substrate, measured 206 
with an increase in absorbance at 410 nm. (a,c) An extensively drug-resistant strain of K. 207 
pneumoniae (ψkp6, AR-0666) exposed to MNM. (a) Comparison in absorbance at 410 nm of K. 208 
pneumoniae with ONPG after MNM exposure, without- and with-light activation. (b,d) An 209 
antibiotic sensitive strain of K. pneumoniae (ψkp7, NIH-1) exposed to MNM. (b) Comparison in 210 
absorbance at 410 nm of K. pneumoniae with ONPG after MNM exposure, without- and with-light 211 
activation. (c-d) ONPG assay at 30 min with Miller calculation for inner membrane permeability 212 
of K. pneumoniae exposed to no MNM (DMSO control), 10 µM of MNM 2 or 10 µM of MNM 1. 213 
Comparison of inner membrane permeability of K. pneumoniae after MNM exposure, without- 214 
and with-light activation. Results presented are means and standard error from four replicates for 215 
each group. (a-c) * p<0.05 are from a one-way ANOVA. (c-d) p-values are from unpaired two-216 
tailed Student t-test. 217 
 218 
We then studied the ability of light-activated MNM 1 to permeabilize the cell wall outer 219 
membrane using an N-phenyl-1-naphthylamine (NPN) uptake assay.25 In both ψkp6 and ψkp7, 220 
light-activated MNM 1 showed a significant increase in NPN partitioning to the cell wall outer 221 
membrane represented by an increase in emission at 430 nm wavelength (Figure 5 a-b). This was 222 
in contrast to both the light-activated MNM 2 and the non-activated MNM 1 that did not cause a 223 
significant increase in emission at 430 nm. These results indicate that light-activated MNM 1 224 
causes disruptions in the cell wall outer membrane allowing the uptake of NPN. 225 
14 
 226 
Figure 5. Cell wall outer membrane permeability and cell membrane integrity with and 227 
without light-activation of molecular nanomachines (MNM). (a-b) Cell wall outer membrane 228 
permeability assay of K. pneumoniae exposed to no MNM DMSO, 10 µM of MNM 2 or 10 µM 229 
of MNM 1. Outer membrane permeability determined by the increase in fluorescence due to the 230 
partitioning of phenylnaphthylamine (NPN) into the cell wall outer membrane, measured by the 231 
increase in emission at 430 nm. Comparison of emission at 430 nm of K. pneumoniae with NPN 232 
15 
after MNM exposure, without- and with-light activation. (a) An extensively drug-resistant strain 233 
of K. pneumoniae (ψkp6, AR-0666) (b) An antibiotic sensitive strain of K. pneumoniae (ψkp7, 234 
NIH-1). (c-d) Cell membrane integrity assay of K. pneumoniae exposed to no MNM (DMSO), 10 235 
µM of MNM 2 or 10 µM of MNM 1. Disruptions in cell membrane integrity determined by 236 
cytoplasmic release of DNA and RNA, measured with an increase in absorbance at 260 nm. 237 
Comparison of absorbance at 260 nm of K. pneumoniae after MNM exposure, without- and with-238 
light activation. (c) An extensively drug-resistant strain of K. pneumoniae (ψkp6). (d) An antibiotic 239 
sensitive strain of K. pneumoniae (ψkp7). Results presented are means and standard error from 240 
four replicates for each group. p-values are from unpaired two-tailed Student t-test. 241 
 242 
To further characterize the extent of the cell wall damage caused by light-activated MNM 243 
1, we assayed the leakage of cytoplasmic constituents using absorbance at 260 nm that detect DNA 244 
and RNA in the supernatant.26 Our studies showed that there was no significant difference in 245 
absorbance at 260 nm or relative changes with light-activated MNM 1, MNM 2 or with no MNM 246 
control in both the K. pneumoniae strains ψkp6 and ψkp7 (Figure 5 c-d). These results indicate 247 
that cell membrane damage caused by light-activated MNM 1 was not large enough to allow the 248 
leakage of cytoplasmic DNA or RNA. 249 
Our K. pneumoniae permeability assays indicate that light-activated MNM 1 is able to 250 
damage both the inner and outer membrane of the cell wall. This allowed smaller molecules such 251 
as enzymes and fluorescent dyes to cross the cell wall, but not larger molecules like DNA or RNA. 252 
The nanomechanical action of MNM 1 was not affected by antibiotic-resistant mechanisms since 253 
it caused cell wall damage to both K. pneumoniae strains alike. 254 
16 
Light-activated MNM 1 combined with meropenem to make an extensively drug 255 
resistant K. pneumoniae more sensitive to meropenem. Carbapenems are last resort antibiotics 256 
used in clinical settings against gram-negative pathogens. Carbapenem antibiotics cause 257 
bactericidal effects through penicillin-binding proteins (PBPs) with the inhibition of cell wall 258 
synthesis.27 Loss of cell wall outer membrane porins is known to contribute to carbapenemase 259 
resistant in K. pneumoniae by acting as a physical barrier preventing carbapenem antibiotics 260 
reaching their target sites in the periplasmic space.28 Since light-activated MNM 1 caused cell wall 261 
damage to K. pneumoniae irrespective of its antibiotic resistant profile, we hypothesized that 262 
MNM 1 will synergize with currently ineffective carbapenem antibiotics to make them more 263 
effective. 264 
To test this hypothesis, we used light-activated MNM 1 with meropenem and tetracycline 265 
(control) at sub-therapeutic concentrations against the extensively drug resistant K. pneumoniae 266 
strain (ψkp6). In contrast to carbapenems, tetracycline antibiotics are protein synthesis inhibitors 267 
that prevent the initiation of translation by binding to the 30S ribosomal subunit.29 We assayed 268 
meropenem at concentrations of 0.5 and 4 µg/mL, and tetracycline 16 and 128 µg/mL. These 269 
concentrations were lower than the MIC and MBC99 against ψkp6 (Table 1). Light-activated MNM 270 
1 and meropenem at concentrations 0.5 and 4 µg/mL showed significant reduction in ψkp6 271 
viability compared to non-activated MNM 1 with same concentrations of meropenem (p=0.0455 272 
and 0.0095, respectively) (Figure 6 a). Light-activated MNM 1 and tetracycline at concentrations 273 
16 and 128 µg/mL did not show a significant reduction in ψkp6 viability. 274 
17 
 275 
Figure 6. Viability reduction of K. pneumoniae with meropenem and light-activated 276 
molecular nanomachines (MNM). Viability reduction of extensively drug-resistant K. 277 
pneumoniae (ψkp6) exposed to antibiotics (meropenem or tetracycline), and no MNM (DMSO), 278 
10 µM of MNM 2 or, 10 µM of MNM 1. (a) Percent viability reduction of K. pneumoniae exposed 279 
to light-activated MNM with no antibiotics (no abx), 0.5 µg/mL meropenem (mero .5), 4 µg/mL 280 
meropenem (mero 4), 16 µg/mL tetracycline (tet 16), or 128 µg/mL tetracycline (tet 128). (b) 281 
18 
Percent survival of K. pneumoniae exposure to different concentrations of meropenem and MNM 282 
with or without light activation. (c) Percent viability reduction of light-activated no MNM, MNM 283 
2 and MNM 1 compared to non-activated controls with different concentrations of meropenem 284 
(0.5 to 64 µg/mL). (d) Percent viability reduction of K. pneumoniae with light-activated MNM 1 285 
with 4 µg/mL meropenem added 30 min before light-activation, 5 min before light-activation or 286 
30 min after light-activation. Percent viability reduction was calculated by comparing light-287 
activated groups with non-activated groups. Results presented are means and standard error from 288 
three replicates for each group. p-values are from unpaired two-tailed Student t-test, compared to 289 
no abx group. *, p<0.05. **, p<0.01. 290 
 291 
When we used various doses of meropenem (0.5 to 64 µg/mL) in combination with 10 µM 292 
of light-activated MNM 1 to study the dose-depended combined effects of the combined therapy 293 
in reducing bacterial viability, as was expected, higher concentrations of meropenem alone showed 294 
increased reductions in viability, with 16 and 64 µg/mL of meropenem showing 70% and 98%, 295 
respectively (Figure 6 b). Without light-activation, MNM 1 or 2 did not have any additional 296 
viability reduction in K. pneumoniae (Figure 6 b). However, when MNM 1 was light-activated for 297 
5 min in combination with meropenem, it caused a significant reduction in bacterial viability 298 
(p<0.05), shifting the survival curve to the left (Figure 6 b). At sub-therapeutic concentrations of 299 
meropenem (4 µg/mL), light-activated MNM 1 caused a 41.7% relative reduction in viability and 300 
at 64 µg/mL of meropenem, the relative reduction in viability was 72% (Figure 6 c). These results 301 
indicate that meropenem when combined with light-activated MNM 1 act to reduce bacterial 302 
viability in an extensively drug-resistant K. pneumoniae strain that is otherwise resistant to 303 
meropenem. 304 
19 
To further characterize the mechanism of interactions between meropenem and light-305 
activated MNM 1, we added meropenem 30 min before, 5 min before and 30 min after light 306 
activation. Our results show that the presence of meropenem during light-activation of MNM 1 307 
showed higher viability reduction in ψkp6 (30 min before, 51.7% and 5 min before, 46.0%), 308 
compared to when added after light-activation (30 min after, 30.7%) (Figure 6 d). This suggests 309 
that there is a temporal relationship between meropenem and light-activated MNM 1, and perhaps 310 
the cell wall damage or perturbation caused by MNM 1 is a transient effect. While we characterized 311 
the temporal aspect of the mechanistic relationship between meropenem and MNM 1, it still needs 312 
more careful characterization. But the MNM alone, disrupting cell walls do result in bacterial 313 
death, albeit slower than in the presence of antibiotics. 314 
Ultrastructural observations show light-activated MNM 1 and meropenem destroy 315 
extensively drug-resistant K. pneumoniae. To further confirm the combined action between 316 
light-activated MNM 1 and 4 µg/mL of meropenem, we exposed ψkp6 to MNM 1 with and without 317 
meropenem and light-activation and observed under transmission electron microscopy (TEM) 318 
(Figure 7). ψkp6 exposed to meropenem and non-activated MNM 1 showed minimal 319 
ultrastructural and morphological changes (Figure 7 a-d). In contract ψkp6 exposed to meropenem 320 
with light-activated MNM 1 showed distinct ultrastructural and morphological changes, many of 321 
which have been attributed to changes with meropenem (Figure 7 e-h).30, 31 These observations 322 
included cell wall disruptions (yellow arrowhead), areas of clear cytoplasm (purple arrowhead), 323 
areas of cytoplasmic leakage (red arrowhead) and bacterial elongation. These observations were 324 
quantified in 60 to 80 ψkp6 per group (Figure 7 i and j). Compared to the control groups, ψkp6 325 
exposed to light-activated MNM 1 and meropenem showed the presence to significantly higher 326 
cell wall disruptions, cytoplasmic clearance and cytoplasmic leakage (P>0.005) (Figure 7 i). The 327 
20 
extent of the ultrastructural damage caused was further quantified as mild, moderate and extensive. 328 
The light-activated MNM 1 and meropenem showed a significantly higher moderate and extensive 329 
ultrastructural damage in ψkp6 compared to the control groups (Figure 7 j). These TEM 330 
observations confirm our viability reduction results where light-activated MNM 1 made sub-331 
therapeutic concentrations of meropenem effective against the extensively drug-resistant K. 332 
pneumoniae strain (ψkp6). 333 
 334 
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Figure 7. Cell wall disruptions and changes in K. pneumoniae exposed to meropenem and 335 
light-activated molecular nanomachines (MNM) observed through transmission electron 336 
microscopy (TEM). (a-d) Representative TEM images of K. pneumoniae incubated with 4 µg/mL 337 
meropenem and 10 µM of non-activated MNM 1 for 2.5 h. (e-h) Representative TEM images of 338 
K. pneumoniae incubated with 4 µg/mL meropenem and 10 µM of light-activated MNM 1 for 2.5 339 
h (30 min prior to 5 min of 395 nm light-activation and 2 h post-light-activation). (a,e) Cross-340 
section of bacilli at 20,000x magnification. (b,f) Longitudinal-section of bacilli at 20,000x 341 
magnification. (c,g) Cross-section of bacilli at 60,000x magnification. (d,h) Longitudinal-section 342 
of bacilli at 60,000x magnification. (a-h) Purple arrowheads show areas of cytoplasmic clearance. 343 
Yellow arrowheads show areas of cell wall disruptions. Red arrowheads show areas of cytoplasmic 344 
leakage. Scale bar for a-b, e-f is 1 µm. Scale bar for c-d, g-h is 0.2 µm. (i-j) Quantification of 345 
changes observed in 60 to 80 K. pneumoniae in each group with exposures to meropenem and 346 
MNM 1. (i) Presence of cell wall disruptions (p=0.0007), areas of cytoplasmic clearance 347 
(p=0.0002), cytoplasmic leakage (p<0.0001) and bacterial elongation (p=0.0022) observed. (j) The 348 
degree of damage observed shown as mild, moderate or extensive for cell wall disruptions 349 
(p=0.0004), number of areas of clear cytoplasm (p=0.0002) and percent clear cytoplasm 350 
(p=0.0003). Results presented are the percentage of bacilli number in each exposure group. One-351 
way ANOVA was used to compare the differences in means of each group. **, p<0.01. 352 
 353 
We used TEM to confirm the combined action of light-activated MNM 1 with meropenem 354 
and showed that upon light-activation, the extensively drug resistant K. pneumoniae undergoes 355 
pathological and morphological changes such as cytoplasmic clearance and bacterial elongation 356 
that are associated with the action of meropenem. The significance of this finding is that light-357 
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activated MNM 1 was able to make a sub-therapeutic concentration effective again. To study the 358 
mechanism of action between meropenem and MNM 1, we examined the temporal effects of 359 
meropenem addition (Figure 7 i). We show that it is important that meropenem be present during 360 
light-activation MNM 1, as the cell wall disruptions could be transient. 361 
Light-activated MNM 1 does not cause cytotoxicity in J774A.1 macrophage cells. The 362 
use of a broad-spectrum nanomechanical antibiotic carries with it the concern of non-specific 363 
damage or associated cytotoxicity to adjacent host cells. To characterize the cytotoxic effects of 364 
light-activated MNM 1 (fast motor) on mammalian cells, we used J774A.1 macrophages and 365 
exposed them to various concentrations of MNM (0.5 to 100 µM) and observed them for up to 24 366 
h post-exposure (Figure 8). We assayed 0.1 % DMSO (solvent) in media and MNM 2 (slow motor) 367 
as negative controls, and MNM 3 (fast motor with TPP, targeting mitochondria) as a positive 368 
control to perform an LDH cytotoxicity assay (Figure 8). At 24 h post-exposure, percent 369 
cytotoxicity observed were as follows: 1% DMSO without light-exposure = 1.8% and with light-370 
exposure = 4.3% (Figure 8 a); 100 µM of MNM 1 without light-activation = 1.6% and with light-371 
activation = 3.9% (Figure 8 b); 100 µM of MNM 2 without light-activation = 3.1% and with light-372 
activation = 5.9% (Figure 8 c); and 100 µM of MNM 3 without light-activation = 76.5% and with 373 
light-activation = 87.2% (Figure 8 d). There was no statistical significance between non-activated 374 
MNM 1 and MNM 2 or no MNM (DMSO) control. This shows that even at a 10x concentration 375 
(100 µM) used against K. pneumoniae, MNM 1 does not display any cytotoxicity in macrophages. 376 
However, when exposed to light, both the no MNM (DMSO) control and MNM 1 showed an 377 




Figure 8. Cytotoxicity of molecular nanomachine (MNM) treatment for J774A.1 381 
macrophages. Percent cytotoxicity of macrophage cells measured with an LDH assay at 0.5, 4 382 
and 24 h exposed to 100 µM MNM without or with light-activation. Percent cytotoxicity was 383 
calculated using a low control (natural cell death) (0%) and a high control (triton-x induced cell 384 
death) (100%) (a) Without MNM (1% DMSO) (p=0.0282). (b) With 100 µM of MNM 1 (fast 385 
motor) in 1% DMSO (p=0.0428). (c) With 100 µM of MNM 2 (slow motor) in 1% DMSO 386 
24 
(p=0.1971). (d) With 100 µM of MNM 3 (fast motor with TPP, targeting mitochondria) in 1% 387 
DMSO (p=0.8748). The DMSO concentration was 1% because 100 µM MNM was assayed. 388 
Results presented are mean and standard error from four replicates. *, p<0.05. 389 
 390 
Light-activated MNM 1 assists meropenem in killing an extensively drug-resistant K. 391 
pneumoniae. Meropenem-resistant K. pneumoniae uses different mechanisms to prevent 392 
meropenem from reaching PBP within peptidoglycan in the periplasmic space. One such resistant 393 
mechanism is a cell wall outer membrane lacking porins that keep meropenem out of the bacteria.23 394 
When MNM 1 is activated with 365 nm light, it rotates unidirectionally at 3 MHz to drill pores 395 
into the cell wall of K. pneumoniae through its nanomechanical action. These pores allow 396 
meropenem to travel across the cell wall outer membrane and reach PBP. This causes the 397 
destruction of the peptidoglycan layer, destabilizing the bacterial cell wall and leading to the death 398 
of K. pneumoniae. This synergistic mechanism between light-activated MNM 1 and meropenem 399 
allows sub-therapeutic concentrations of meropenem to kill meropenem resistant, extensively 400 
drug-resistant K. pneumoniae. 401 
There are a few limitations in this study. MNM 1 has a non-specific action, without any 402 
specific binding affinity to K. pneumoniae. When MNM 1 was previously used to target and 403 
permeabilize cancer cells, they had short sequence peptides that allowed selective binding and high 404 
cell specificity. Targeting specific bacterial receptors using ligands can increase the specificity to 405 
the pathogen.32 Several ligands including aGM1, aGM2, and GM2 have been shown to have 406 
specificity to K. pneumoniae and can be attached to the MNM stator to increase their specificity 407 
and efficacy.33-35 408 
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Another concern of the non-specific nature of MNM 1 is the toxicity and possible damage 409 
it can cause to surrounding host cells during light-activation. In order to address this issue, we 410 
looked at the cytotoxicity of MNM 1 in macrophages (Figure 8). We only observed a 1.6% 411 
cytotoxicity with 100 µM (10x more) MNM 1. However, with 365 nm light-exposure, the 412 
macrophage cytotoxicity increased to 3.9-5.9% (p-value <0.05), highlighting the concerns with 413 
this use of 365 nm light. This also limited our MNM 1 activation time to 5 min since 365 nm light 414 
displayed higher bactericidal effects over longer exposure times (Figure 2 c). To address this, we 415 
are in the process of developing 405 nm light-activated MNM that will be safer and allow longer 416 
activation times. 417 
A wavelength of 365 nm has relatively low penetration in host organs and tissue. This 418 
currently limits the use of MNM for the potential treatment of deep tissue infections, as MNM will 419 
not be activated effectively. We are also exploring the synthesis of next generation MNM that are 420 
activated with longer wavelengths (>700 nm) in the near infrared (NIR) region. This will greatly 421 
increase the ability of MNM activation in much deeper host targets and also allow the activation 422 
of MNM for longer times to achieve a far superior antimicrobial efficacy, without any associated 423 
harmful effects on the host. However, the energies at these wavelengths are much lower. We have 424 
been exploring 2-photon NIR, albeit the potential depth may be somewhat limited, this approach 425 
would allow very precise targeting within tissues36.  426 
Our current study characterizes the use of light-activated MNM 1 as an effective 427 
nanomechanical antibacterial agent against extensively-drug-resistant K. pneumoniae. In addition 428 
to its ability to counter antibacterial resistance, light-activated MNM 1 has several potential 429 
therapeutic applications. It can be used to treat skin infections, wound infections and urinary tract 430 
infections caused by many pathogens due to its broad-spectrum activity. Light-activated MNM 1 431 
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has the potential to disrupt biofilms on indwelling prosthetic devices thereby allowing the 432 
antibiotic treatment to be more efficacious against biofilm forming pathogens. 433 
Conclusions 434 
In this study, we show that light-activated MNM 1 display antibacterial properties against 435 
K. pneumoniae that is not diminished even in an extensively drug resistant strain (Figure 3). This 436 
is because bacterial antimicrobial resistance mechanisms are not developed against a 437 
nanomechanical agent that disrupts bacterial cell walls. We have shown the ability of light-438 
activated MNM 1 to disrupt cell walls by its nanomechanical action; using K. pneumoniae cell 439 
wall IM and OM permeability assays (Figure 4 and 5). The ability to use nanomechanical force to 440 
disrupt bacterial cell walls is a unique feature of MNM with the potential of many therapeutic 441 
applications and has not been characterized before. With only 5 min of MNM 1 light-activation, 442 
we observed 14 – 17% in viability reduction of K. pneumoniae. Next we show that light-activated 443 
MNM 1 can combine with meropenem at sub-therapeutic concentrations to be effective against an 444 
extensively-drug-resistant K. pneumoniae strain (Figure 6). The ability to help otherwise 445 
ineffective antibiotics to be efficacious is another unique aspect of light-activated MNM 1. The 446 
use of MNM 1 in combination with other conventional antibiotic allows the potential recycling of 447 
many currently available antibiotics against MDR pathogens. 448 
Methods 449 
Bacterial strains. Two clinical strains of K. pneumoniae were used. An extensively drug-450 
resistant K. pneumonia, AR-0666 (ψkp6) obtained from the CDC and a KPC-negative antibiotic 451 
sensitive strain, NIH-1 (ψkp7) obtained from the National Institutes of Health (NIH). 452 
27 
Synthesis of Molecular Machines.  The molecular motors 1 and 2 were freshly prepared 453 
according to our previous protocols.17, 36 The molecular motor 3 is new-designed and synthesized 454 
as described in the Supplementary Information. 455 
Molecular nanomachines (MNM). MNM 1 is a fast motor with a rotor that rotates at 2-3 456 
x 106 revolutions per second relative to its stator (Figure 1 b). MNM 2 is a slow motor that rotates 457 
about 1.8 revolutions per hour (Figure 1 c). MNM 2 served as a negative control. MNM 3 is MNM 458 
1 attached to triphenylphosphonium (TPP) cation at the stator (Figure 1 d). TPP targets eukaryotic 459 
mitochondria and was used to demonstrate eukaryotic cell targeting of MNM. 460 
Minimal inhibitory concentration (MIC) and minimal bactericidal concentration 461 
(MBC99) of antibiotics in K. pneumoniae. Log-phase K. pneumoniae cultures (4-5 x 105 462 
CFU/mL) grown in Mueller-Hinton broth (MHB) were exposed to antibiotics for 16 h in 96-well 463 
plates in triplicates. 1:2 serial dilutions of each antibiotic were assays in a microdilution assay 464 
against K. pneumoniae. Perkin Elmer EnVision microplate reader was used to measure culture 465 
optical density (OD) at 600 nm. After antibiotic exposure, bacterial cultures were plated for 466 
CFL/mL counts. The MIC and MBC99 values were calculated relative to the starting CFU/mL. 467 
MIC was defined as the minimal concentration of antibiotic needed to inhibit the growth of the 468 
starting culture of bacteria (≤100%). MBC99 was defined as the minimal concentration of the 469 
antibiotic needed to kill 99% of the starting culture of bacteria (≤1%). 470 
K. pneumoniae viability reduction assay. Log-phase K. pneumoniae cultures (2-4 x 105 471 
CFU/mL) grown in Lysogeny broth (LB) were exposed to MNM in triplicates. The concentration 472 
of MNM used was 10 µM in 0.1% DMSO K. pneumoniae cultures were incubated with MNM for 473 
30 minutes prior to 5 min of 365 nm light-activation. 365 nm light source was placed directly 474 
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above the cultures at a constant distance of 1.3 cm (Figure 1 d). After light exposure, bacterial 475 
cultures were plated for CFL/mL counts. 476 
Inner membrane permeability assay. K. pneumoniae (2-4 x 105 CFU/mL) was washed 477 
once with 10 mM sodium phosphate (pH 7.4) and resuspended in the same buffer containing 1.5 478 
mM ortho-nitrophenyl-β-galactoside (ONPG).24 Cultures were incubated with 10 µM MNM in a 479 
black 96-well plate with clear bottoms with 100 µL of K. pneumoniae in four replicates. MNM 480 
were light-activated for 5 min with the light source placed directly above the 96-well plate (Figure 481 
2 e). The production of o-nitrophenol was monitored at an absorbance of 410 nm every 3 min for 482 
45 min post-light-exposure. Miller calculation was used to determine the inner membrane 483 
permeability. 484 
Outer membrane permeability assay. K. pneumoniae (2-4 x 105 CFU/mL, 100 µL) was 485 
incubated with 10 µM MNM in a black 96-well plate with clear bottoms for 30 min and then light-486 
activated for 5 min, in 4 replicates (Figure 2 e). After light-activation, 10 mM 1-N-487 
phenylnaphthylamine (NPN) was mixed and incubated for 30 min. The fluorescence intensity due 488 
to the partitioning of NPN into the OM was measured with a microplate reader fluorescence 489 
spectrophotometer with an excitation wavelength of 350 nm and an emission wavelength of 430 490 
nm. 491 
Cell membrane integrity assay. Similar to the OM permeability assay, K. pneumoniae 492 
was exposed to MNM and light-activated for 5 min in 4 replicates. These cultures were spun down 493 
at 10,000 rpm and the supernatant was placed in a 96-well plate. The release of cytoplasmic 494 
constituents of the cell was monitored using the absorbance at 260 nm.26 495 
MNM and meropenem combined assay. Similar to viability reduction assays, ψkp6 496 
cultures (2-4 x 105 CFU/mL) were incubated with 10 µM of MNM and meropenem for 30 min 497 
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and activated with 365 nm light for 5 min in triplicates. Different concentrations of meropenem 498 
(0,5, 4, 16, and 64 µg/mL) was used with 10 µM of MNM. Tetracycline (16 and 128 µg/mL) was 499 
used as an antibiotic control with MNM. These cultures were then plated for CFU/mL counts. 500 
Transmission electron microscopy (TEM). Log-phase ψkp6 (5 x 106 CFU/mL) were 501 
exposed to 10 µM of MNM 1 and 4 µg/mL of meropenem with and without light-activation for 502 
TEM. The four exposure groups were: (a) MNM 1 only, without light-activation, (b) MNM 1 only, 503 
with light-activation, (c) MNM 1 with meropenem, without light-activation and (d) MNM 1 with 504 
meropenem, with light-activation. Post-exposure, K. pneumoniae was incubated with meropenem 505 
for an additional 2 h. Then they were fixed with 4% formaldehyde, 2.5% glutaraldehyde and 1% 506 
acrolein. After 3x washes, they were embedded in Epon 812 resin and stained with 5% uranyl 507 
acetate. The embedded samples will be sectioned into grids and imaged with JEOL 1200 TEM. 508 
Cell wall disruptions, cytoplasmic clearance, cytoplasmic leakage, and bacterial elongation were 509 
quantified using 60-80 ψkp6 for each group. 510 
Macrophage cytotoxic assay. A lactate dehydrogenase (LDH) cytotoxicity colorimetric 511 
assay kit (Biovision, #K311) was used to measure the cytotoxicity of MNM at different 512 
concentrations (0.5, 1, 10, 50 and 100 µM) in a J774A.1 macrophage cell line. J774A.1 cells (5 x 513 
105 cells/mL) grown in DMEM media with 10% FBS were incubated with MNM in a 96-well 514 
plate (100 µL in each well) and exposed to 5 min of 365 nm light (Figure 2 f, 8 and d). Cytotoxicity 515 
of MNM with and without light activation was measured at 0.5, 4 and 24 h post exposure. DMSO 516 
and MNM 2 were used as negative controls. MNM 3 was used as a cell targeted positive control. 517 
Statistical analyses. All experiments were done with at least three replicates (n ≥ 3). The 518 
number of replicates used in each experiment is stated in the figure legend of each experiment. 519 
Prism GraphPad was used to perform two‐tailed unpaired Student t‐test statistical analyzes to 520 
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compare the means of two exposure groups. For comparison among 3 or more groups, analysis of 521 
variance (ANOVA) was used. A Mann–Whitney U test was used to compare different survival 522 
plots. Means and standard errors are presented in each of the graphs plotted in Microsoft Excel. P 523 
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Model illustrating the combined action of molecular nanomachine (MNM) 1 nanomechanical 644 
action and meropenem on K. pneumoniae. A meropenem resistant K. pneumoniae exposed to 645 
sub-therapeutic concentrations meropenem (4 µg/mL) and MNM 1 has no reduction in bacterial 646 
viability. Meropenem is unable to reach its target sites within the periplasmic space, due to resistant 647 
mechanisms on the cell wall outer membrane. Light-activation of MNM 1 causes it to rotate 648 
vigorously and drill pores on the cell wall through its nanomechanical action. This allows 649 
meropenem to cross the outer membrane and display improved meropenem activity resulting in 650 
bactericidal effects. This synergistic mechanism between light-activated MNM 1 and meropenem 651 
allows sub-therapeutic concentrations of meropenem to kill a meropenem resistant, extensively 652 
drug-resistant K. pneumoniae. 653 
 654 
